Key facts
- This page summarizes Alan B. Sandler's Form 4 filing for Zai Lab Ltd (ZLAB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Jun 2022, 21:44.
Alan B. Sandler - 25 Jun 2022 Form 4 Insider Report for Zai Lab Ltd (ZLAB)
- Reporting relationship
- Head of Global Dev., Oncology
- Issuer ticker
- ZLAB
- Reported as of
- 25 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2022, 21:44:06 UTC
- Prior SEC filing
- 05 Apr 2022
- Next SEC filing
- 08 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bruce Blefeld, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan B. Sandler filed Form 4 for Zai Lab Ltd (ZLAB) on 27 Jun 2022.
Change
- Previous filing in this sequence was filed on 05 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZLAB
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +73,000
- Change %
- Price
- $0.000000
- Shares after
- 73,000
- Date
- 25 Jun 2022
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 73,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Share Unit represents a contingent right to receive one American Depositary Share (ADS), which represents ten Ordinary Shares of the issuer.
Footnote F2
The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.